Molecular pathology of familial hypercholesterolemia, related dyslipidemias and therapies beyond the statins.

doi:10.3109/10408363.2011.646942

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Molecular pathology of familial hypercholesterolemia, related dyslipidemias and therapies beyond the statins.

Critical reviews in clinical laboratory sciences - 1 Jan 2000

Faiz Fathimath, Hooper Amanda J, van Bockxmeer Frank M

Abstract excerpt

The development of the statin class of cholesterol-lowering drugs is one of the most significant success stories of modern pharmacotherapy. World-wide there are an estimated 150 million people on statins, with the emerging economies of India and China predicted to contribute significantly to that number. Notwithstanding their success, a significant number of people cannot tolerate statins because of serious side...

Topics

Dyslipidemias
Genetic Predisposition to Disease
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hyperlipoproteinemia Type II
RNA Splice Sites
Receptors, LDL

Source

Open in PubMed

Identifiers

PMID: 22214202
DOI: 10.3109/10408363.2011.646942

Genes

LDLR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics